Cited 41 times in
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-Week, multicenter, randomized, open-label, dose-titration study in Korean patients with Hypercholesterolemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상학 | - |
dc.contributor.author | 정남식 | - |
dc.date.accessioned | 2014-12-21T16:33:38Z | - |
dc.date.available | 2014-12-21T16:33:38Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/95916 | - |
dc.description.abstract | BACKGROUND: Although previous studies have examined the efficacy of pitavastatin, its tolerability and effects on lipid concentrations have not been compared with those of atorvastatin in a multicenter, randomized study. OBJECTIVE: This trial compared the efficacy and tolerability of pitavastatin and atorvastatin in hypercholesterolemic Korean adults. METHODS: This 8-week, multicenter, randomized, open-label, dose-titration study was conducted at 18 clinical centers in Korea between May 2005 and February 2006. After a 4-week dietary lead-in period, patients with hypercholesterolemia were randomized to receive either pitavastatin 2 mg/d or atorvastatin 10 mg/d. Patients who had not reached the low-density lipoprotein cholesterol (LDL-C) goal by week 4 received a double dose of the assigned medication for an additional 4 weeks. Efficacy was evaluated in terms of achievement of the National Cholesterol Education Program Adult Treatment Panel III LDL-C goals and changes from baseline in other lipids and high-sensitivity C-reactive protein (hs-CRP). The tolerability profile was assessed by physical and electro-cardiographic examinations, laboratory tests, and recording adverse reactions at all visits. RESULTS: A total of 268 patients were randomized to treatment, and 222 (82.8%) completed the study (149 women, 73 men; mean age, 59 years; mean weight, 63.5 kg). At the end of the study, there was no significant difference between the pitavastatin and atorvastatin groups in the proportion of patients achieving the LDL-C goal (92.7% [102/110] vs 92.0% [103/112], respectively). In addition, there were no significant differences between groups in terms of the percent changes from baseline in LDL-C, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), or hs-CRP. Twenty-six of 136 patients (19.1%) taking pitavastatin reported 35 treatment-emergent adverse reactions; 33 of 132 patients (25.0%) taking atorvastatin reported 39 treatment-emergent adverse reactions. Elevations in creatine kinase were observed in 6 patients (4.4%) in the pitavastatin group and 7 patients (5.3%) in the atorvastatin group. There were no serious adverse drug reactions in either group. CONCLUSIONS: In these adult Korean patients with hypercholesterolemia, pitavastatin and atorvastatin did not differ significantly in terms of the proportions of patients achievi | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 2365~2373 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-Week, multicenter, randomized, open-label, dose-titration study in Korean patients with Hypercholesterolemia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Sang Hak Lee | - |
dc.contributor.googleauthor | Namsik Chung | - |
dc.contributor.googleauthor | Min Su Hyon | - |
dc.contributor.googleauthor | Seong Wook Han | - |
dc.contributor.googleauthor | Si-Wan Choi | - |
dc.contributor.googleauthor | Kwang-Soo Cha | - |
dc.contributor.googleauthor | Myeong-Ho Yoon | - |
dc.contributor.googleauthor | Kyeong Ho Yun | - |
dc.contributor.googleauthor | Tae Hoon Ahn | - |
dc.contributor.googleauthor | Wan-Joo Shim | - |
dc.contributor.googleauthor | Yung Woo Shin | - |
dc.contributor.googleauthor | Dong Gu Shin | - |
dc.contributor.googleauthor | Hong Seog Seo | - |
dc.contributor.googleauthor | Si Hoon Park | - |
dc.contributor.googleauthor | Hyun Seung Kim | - |
dc.contributor.googleauthor | Chee Jeong Kim | - |
dc.contributor.googleauthor | Won Ho Kim | - |
dc.contributor.googleauthor | Doo-Il Kim | - |
dc.contributor.googleauthor | Jun Kwan | - |
dc.identifier.doi | 10.1016/j.clinthera.2007.11.002 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03585 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J00614 | - |
dc.identifier.eissn | 1879-114X | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0149291807003517 | - |
dc.contributor.alternativeName | Lee, Sang Hak | - |
dc.contributor.alternativeName | Chung, Nam Sik | - |
dc.contributor.affiliatedAuthor | Chung, Nam Sik | - |
dc.contributor.affiliatedAuthor | Lee, Snag Hak | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 29 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2365 | - |
dc.citation.endPage | 2373 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, Vol.29(11) : 2365-2373, 2007 | - |
dc.identifier.rimsid | 53287 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.